Trial *
Publication Ahmad B, Clin Med Res (2021) (published paper)
Dates: 2020-06-01 to 2020-06-15
Funding: No specific funding (The authors have reported no conflicts of interest or financial support for this work.)
Conflict of interest: No

Methods
RCT
Blinding: single blinding
Location : Single center / Pakistan
Follow-up duration (days): 12
Inclusion criteria
  • Adults
  • admitted into the hospital
  • COVID confirmed by PCR
  • mild to moderate symptoms as per Chinese guidelines for COVID-19
Exclusion criteria
  • Severe or critical COVID-19
  • pregnant women
  • ischemic heart disease or cardiac arrhythmias
  • retinopathy
  • patients who refused to participate in the study
Interventions
Treatment
Hydroxychloroquine
Initial dose: 400 mg orally twice a day on day 1 - Maintenance dose: 200 mg orally twice a day on days 2-5

Chloroquine
250 mg orally twice a day for 7 days
Control
Placebo

Participants
Randomized
participants :
Hydroxychloroquine=50
Chloroquine=50
Placebo=50
Characteristics of participants
N= 150
Mean age : NR
0 males
Severity : Mild: n=* / Moderate: n=* / Severe: n=0 Critical: n=0
Number of vaccinated participants: 0
Primary outcome
In the register
NR
In the report
Development of cytokine release syndrome (CRS)
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing willing stated in the publication:

Not reported
Risk of bias
Overall
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
Some concerns
General comment Only the published article was used in data extraction and assessment of risk of bias. No registry, protocol or statistical analysis plan was available. The article reported no NMA-specific outcomes eligible for extraction.